Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial.

ESC Heart Fail · 2025 · PMC12287836 · PMID 40207405

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

did not reach statistical significanceP = 0.067so close (0.05 < p ≤ 0.1)

Although reductions in LVM and LVMI were more pronounced in the dapagliflozin group, these differences did not reach statistical significance (ΔLVM −21.18 ± 58.47 g vs. −1.26 ± 49.10 g, P = 0.067; ΔLVMI −12.29 ± 34.33 g/m 2 vs. −0.51 ± 28.94 g/m 2 , P = 0.066).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.